Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01912560 · ClinicalTrials.gov registry record · Phase 2
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Phase 2 study of Hypercholesterolemia and Dyslipidemia, sponsored by Catabasis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 14
- Study locations
NCT01912560: Completed Phase 2 study of Hypercholesterolemia and Dyslipidemia, sponsored by Catabasis Pharmaceuticals.
NCT01912560 is a Phase 2 study of Hypercholesterolemia and Dyslipidemia that has completed, run by Catabasis Pharmaceuticals. The registered enrollment target is 99 participants, below the 815-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (88% lower). The trial reports 14 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01912560, a Phase 2 study of Hypercholesterolemia and Dyslipidemia, has completed, sponsored by Catabasis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to determine the safety and efficacy of different doses of CAT-2003 in patients with hyperlipidemia when CAT-2003 is taken for 4 weeks. The study will evaluate effects of CAT-2003 on (1) fasting triglycerides and non-HDL-C in patients with moderate hypertriglyceridemia and (2) fasting LDL-C levels in combination with a statin in patients with hypercholesterolemia who are on a statin.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Statin
- DRUG CAT-2003
Study Locations (14)
Florida
- - Jacksonville
- - Miami
- - Winter Park
Ohio
- - Cincinnati
- - Cincinnati
- - Cincinnati
North Carolina
- - Raleigh
- - Raleigh
Alabama
- - Muscle Shoals
California
- - Los Angeles
Kansas
- - Kansas City
Kentucky
- - Louisville
Maine
- - Auburn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2013-07 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
What the finished NCT01912560 record still lists
NCT01912560 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 815-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (88% lower).
The record links to 3 conditions, with Hypercholesterolemia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01912560 lists 14 locations in 9 states (Florida, Ohio, North Carolina).
Frequently Asked Questions
What is clinical trial NCT01912560 about?
NCT01912560 is a clinical study titled "Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia". The purpose of this study is to determine the safety and efficacy of different doses of CAT-2003 in patients with hyperlipidemia when CAT-2003 is taken for 4 weeks. The study will evaluate effects of CAT-2003 on (1) fasting triglycerides and non-HDL-C in patients with moderate hypertriglyceridemia a...
What is the current status of trial NCT01912560?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2013-07. Estimated completion is 2013-12.
What conditions does trial NCT01912560 study?
This clinical trial studies the following conditions: Hypercholesterolemia, Dyslipidemia, Hypertriglyceridemia.
What interventions are being tested in trial NCT01912560?
The interventions under investigation include: Placebo (DRUG), Statin (DRUG), CAT-2003 (DRUG).
Who is sponsoring clinical trial NCT01912560?
This trial is sponsored by Catabasis Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01912560 being conducted?
This trial has 14 study locations across Alabama, California, Florida, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01912560's enrollment target sits among peer trials
99 40th of 62 higher than 23 of 62 other Hypercholesterolemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypercholesterolemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia
COMPLETED · Phase 2
-
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
COMPLETED · Phase 2
-
Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
COMPLETED · Phase 2
-
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
COMPLETED · Phase 2
-
Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia